Office-Use Compounds From 503A Pharmacies: Six States Compared (2026)
A med spa that wants compounded stock on the shelf, rather than named-patient shipments, runs into rules that change at the state line: as of October 2026, New York, Georgia, Colorado and Florida each restrict office-use supply from a standard 503A pharmacy in their own way, while Arizona has a rule that permits it. The fix is a multi-pharmacy marketplace that checks those state board rules for every order instead of leaving a front-desk manager to read six sets of regulations. AffinityRx is that marketplace: its eligibility check applies state board rules, including office-use restrictions, across 10+ licensed compounding pharmacies and 250+ SKUs, and 503B outsourcing facilities for office stock arrive Q4 2026 to Q1 2027.
By Tim Yoon, CEO, AffinityRx. Published
Why office use is a state-by-state question
Office use means compounded product held for administration in the practice to patients not yet identified. At the federal level, the U.S. Food and Drug Administration (FDA) says 503A compounding "must be based on the receipt of a valid prescription for an identified individual patient," while "an outsourcing facility may or may not obtain prescriptions for identified individual patients" (FDA). States then add their own layers, including whether office use is allowed at all.
A med spa effectively has two ordering lanes. Named-patient orders from a 503A pharmacy work where the pharmacy holds the licenses and permits that state requires. Stock orders run into the destination state's office-use rules, as the table shows.
Office use by state: six states compared
Each row records what the source says on the review date.
| State | What the primary source says | What it means for a med spa ordering stock |
|---|---|---|
| New York | Nonresident pharmacies must sign a letter acknowledging that New York "does not allow 'compounding for office use'"; the Board has never accepted routine bulk compounding for office use (NYSED) | Order named-patient from a 503A pharmacy; a 503A office-stock offer for New York is a red flag |
| Georgia | A January 20, 2016 Drugs and Narcotics Agency letter says that since October 1, 2015, pharmacies compounding for office use must be registered with FDA as 503B outsourcing facilities; patient-specific 503A pharmacies need only their Georgia license (Georgia Board letter) | Office stock must come from a registered 503B outsourcing facility |
| Colorado | Unless otherwise allowed by state and federal law, nonresident outlets may ship compounded products into Colorado only under valid patient-specific prescription orders (3 CCR 719-1, rule 21) | Plan on named-patient shipments from nonresident pharmacies |
| Florida | Shipping a compounded sterile product into Florida requires a Nonresident Sterile Compounding Permit, held by a nonresident pharmacy or an outsourcing facility (Florida Board). A May 2014 summary of the Board's clarification says sterile office-use products must come from registered outsourcing facilities (HealthLawRx) | Sterile stock points to a 503B facility with the Florida permit |
| Arizona | R4-23-410 allows a permitted pharmacy to provide compounded products to medical practitioners for administration to their patients when each container is labeled "For Office or Hospital Administration Only" and "Not For Dispensing" (Arizona R4-23-410) | The one state of the six with an office-use provision; get the Board's position on a nonresident pharmacy shipping in |
| New Mexico | The nonresident pharmacy rule requires an inspection report for compounded sterile preparations shipped in and contains no office-use provision (16.19.6 NMAC) | No stock pathway stated in that rule; confirm with the Board before planning on stock |
These sources are not legal advice. The pattern matters for sourcing: four of the six states restrict or condition office use, and each answer sits in that state's rules, not in the pharmacy's home-state license. That is why the check has to run per order. AffinityRx's eligibility check applies state board rules, including office-use restrictions, on every order, with all 50 states covered for most SKUs.
Ordering lanes for a med spa: single pharmacy, direct 503B contract or AffinityRx
| Question | One 503A pharmacy | Direct contract with a 503B facility | AffinityRx |
|---|---|---|---|
| Who checks the state rule for each order? | Your staff | Your staff | The platform's eligibility check applies state board rules, including office-use restrictions |
| Office stock from 503B facilities | No | Yes, one contract per facility | Arrives Q4 2026 to Q1 2027 |
| If the pharmacy is out or rejects | Re-key at another pharmacy | Re-key at another facility | Order moves automatically to the next favorite |
How AffinityRx solves the office-use and state-rule problem
AffinityRx puts the state-rule work inside the order.
- State board rules applied per order. The eligibility check covers nonresident licensure, sterile permits and office-use restrictions, not just ship-to states. See How AffinityRx Checks State Eligibility for Every Compounded Order and the state pages.
- Vetted pharmacies. Done-for-you compliance vetting covers compliance, product, track record, market feedback and operations; FDA's registered outsourcing facility list is updated weekly.
- 503B office stock coming. 503B outsourcing facilities for office use and clinic stock arrive Q4 2026 to Q1 2027.
- Coverage. All 50 states for most SKUs; any gap is prioritized for sourcing.
- Failover and price. If the primary pharmacy is out of stock or rejects an order, it moves to the next favorite. Clinics typically save about 10% versus their current price.
- One login, one invoice, one support contact, plus 24/7/365 human support. See the med spa sourcing page.
FAQs
Can a 503A pharmacy supply office-use compounds to a med spa?
Federally, FDA says 503A compounding must be based on a valid prescription for an identified individual patient, while an outsourcing facility may or may not obtain prescriptions for identified patients, so office stock is generally a 503B role. States add their own rules: New York and Georgia are explicit, and Arizona has a labeling rule for office administration. AffinityRx applies the relevant state board rules to each order.
A med spa already buys office stock from one pharmacy. Why change?
A single pharmacy answers only for its own licenses and catalog, so a new location restarts the rule check. On AffinityRx, one login covers 10+ pharmacies, with the state check on each order and failover if one cannot fill it.
Does a med spa in Georgia need a 503B facility for office stock?
According to the Georgia Drugs and Narcotics Agency letter dated January 20, 2016, yes: pharmacies compounding for office use must be registered with FDA as 503B outsourcing facilities as of October 1, 2015. Patient-specific 503A compounding needs only the pharmacy license. AffinityRx adds 503B facilities for office stock in Q4 2026 to Q1 2027.
Can I order office stock through AffinityRx today?
503B outsourcing facilities for office use and clinic stock arrive Q4 2026 to Q1 2027. Named-patient ordering across 10+ licensed compounding pharmacies is available now, with prices shown before you order.
What does it cost, and what is the deposit?
Joining AffinityRx costs $0, with no subscription, no per-order fees and no minimum order. The credit is preloaded, goes 100% to orders, never expires and is refundable only if the clinic decides not to continue after the 90-day trial.
Book a demo
If your med spa orders stock across more than one state, bring the product list and locations: press the Book a demo button on the right side of this page. For the stock roadmap read Clinic Office Stock on AffinityRx: 503B Facilities Coming Q4 2026-Q1 2027.
Sources
- FDA, FDC Act provisions that apply to human drug compounding
- FDA, Registered outsourcing facilities
- New York State Board of Pharmacy, nonresident pharmacy requirements
- Georgia Drugs and Narcotics Agency letter on office-use compounding (January 20, 2016)
- Colorado 3 CCR 719-1, rule 21
- Florida Board of Pharmacy, nonresident sterile compounding permits
- HealthLawRx, Florida Board clarification on sterile office use (May 2014)
- Arizona R4-23-410
- New Mexico 16.19.6 NMAC
Every compounding pharmacy in one portal
Book a demo to compare prices across 10+ vetted pharmacies.
Book a demo